Epigallocatechin-3-gallate inhibits osteogenic differentiation of vascular smooth muscle cells through the transcription factor JunB
Acta Biochimica et Biophysica Sinica · 2025
DOI: 10.3724/abbs.2024060 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Biochimica et Biophysica Sinica, 2025. Verfasst von Tiantian Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biomedical Engineering, West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu 610041, China. Hauptthemen laut MEDLINE: Catechin, Osteogenesis, Cell Differentiation, Muscle, Smooth, Vascular. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Medial arterial calcification (MAC) accompanying chronic kidney disease (CKD) leads to increased vessel wall stiffness, myocardial ischemia, heart failure, and increased cardiovascular morbidity and mortality. Unfortunately, there are currently no drugs available to treat MAC. The natural polyphenol epigallocatechin-3-gallate (EGCG) has been demonstrated to protect against cardiovascular disease; however, whether EGCG supplementation inhibits MAC in CKD remains unclear. In this study, we utilize a CKD-associated MAC model to investigate the effects of EGCG on vascular calcification and elucidate the underlying mechanisms involved. Our findings demonstrate that EGCG treatment significantly reduces calcium phosphate deposition and osteogenic differentiation of VSMCs in vivo and in vitro in a dose-dependent manner. In addition, through RNA sequencing (RNA-seq) analysis, we show a significant activation of the transcription factor JunB both in CKD mouse arteries and in osteoblast-like VSMCs. Notably, EGCG effectively suppresses CKD-associated MAC by inhibiting the activity of JunB. In addition, overexpression of JunB can abolish while knockdown of JunB can enhance the inhibitory effect of EGCG on the osteogenic differentiation of VSMCs. Furthermore, EGCG supplementation inhibits MAC in CKD via modulation of the JunB-dependent Ras/Raf/MEK/ERK signaling pathway. In conclusion, our study highlights the potential therapeutic value of EGCG for managing CKD-associated MAC, as it mitigates this pathological process through targeted inactivation of JunB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Biomedical Engineering, West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu 610041, China.
- West China School of Pharmacy, Sichuan University, Chengdu 610041, China.
- Department of Cardiology, the Third People's Hospital of Chengdu, Affiliated Hospital of Southwest Jiaotong University, Chengdu 610000, China.
- Key Laboratory for Biorheological Science and Technology of Ministry of Education, State and Local Joint Engineering Laboratory for Vascular Implants, Bioengineering College of Chongqing University, Chongqing 400030, Ch…
- JinFeng Laboratory, Chongqing 401329, China.
- Department of Physiology, West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu 610041, China.
Zitieren
APA
Li, T., Fang, F., Yin, H., Zhang, Z., Wang, X., Wang, E., Yu, H., Shen, Y., Wang, G., He, W., & Liu, X. (2025). Epigallocatechin-3-gallate inhibits osteogenic differentiation of vascular smooth muscle cells through the transcription factor JunB. Acta Biochimica et Biophysica Sinica. https://doi.org/10.3724/abbs.2024060
Vancouver
Li T, Fang F, Yin H, Zhang Z, Wang X, Wang E, et al. Epigallocatechin-3-gallate inhibits osteogenic differentiation of vascular smooth muscle cells through the transcription factor JunB. Acta Biochimica et Biophysica Sinica. 2025. doi:10.3724/abbs.2024060
BibTeX
@article{Li2025,
author = {Li, Tiantian and Fang, Fei and Yin, Hongmei and Zhang, Zhen and Wang, Xiangxiu and Wang, Erxiang and Yu, Hongchi and Shen, Yang and Wang, Guixue and He, Weihong and Liu, Xiaoheng},
title = {Epigallocatechin-3-gallate inhibits osteogenic differentiation of vascular smooth muscle cells through the transcription factor JunB},
journal = {Acta Biochimica et Biophysica Sinica},
year = {2025},
doi = {10.3724/abbs.2024060}
}
EUVIMED